NasdaqGS:AMRS

Stock Analysis Report

Executive Summary

Amyris, Inc. operates as an integrated renewable products company.


Snowflake Analysis

High growth potential and slightly overvalued.


Similar Companies

Share Price & News

How has Amyris's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AMRS has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-4.0%

AMRS

-3.6%

US Chemicals

-4.2%

US Market


1 Year Return

-28.8%

AMRS

-9.8%

US Chemicals

14.0%

US Market

Return vs Industry: AMRS underperformed the US Chemicals industry which returned -9.8% over the past year.

Return vs Market: AMRS underperformed the US Market which returned 14% over the past year.


Shareholder returns

AMRSIndustryMarket
7 Day-4.0%-3.6%-4.2%
30 Day15.3%-2.7%-1.8%
90 Day-18.1%-3.6%2.6%
1 Year-28.8%-28.8%3.4%-9.8%16.3%14.0%
3 Year-57.1%-57.1%24.2%0.4%43.2%34.0%
5 Year-91.1%-91.1%32.7%3.9%65.9%47.6%

Price Volatility Vs. Market

How volatile is Amyris's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Amyris undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: AMRS ($3.28) is trading below our estimate of fair value ($34.71)

Significantly Below Fair Value: AMRS is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: AMRS is unprofitable, so we can't compare its PE Ratio to the Chemicals industry average.

PE vs Market: AMRS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AMRS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AMRS has negative assets, so we can't compare its PB Ratio to the US Chemicals industry average.


Next Steps

Future Growth

How is Amyris forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

61.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AMRS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).

Earnings vs Market: AMRS is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: AMRS's is expected to become profitable in the next 3 years.

Revenue vs Market: AMRS's revenue (31% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: AMRS's revenue (31% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AMRS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Amyris performed over the past 5 years?

-20.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AMRS is currently unprofitable.

Growing Profit Margin: AMRS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AMRS is unprofitable, and losses have increased over the past 5 years at a rate of -20.5% per year.

Accelerating Growth: Unable to compare AMRS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AMRS is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-15.9%).


Return on Equity

High ROE: AMRS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Amyris's financial position?


Financial Position Analysis

Short Term Liabilities: AMRS has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: AMRS has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: AMRS has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: AMRS's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: AMRS has a high level of physical assets or inventory.

Debt Coverage by Assets: AMRS has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AMRS has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: AMRS has less than a year of cash runway if free cash flow continues to reduce at historical rates of -4.8% each year


Next Steps

Dividend

What is Amyris's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage2.3%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate AMRS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate AMRS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AMRS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AMRS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AMRS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

John Melo (53yo)

13.1yrs

Tenure

US$9,638,012

Compensation

Mr. John G. Melo has been the Chief Executive Officer at Amyris, Inc. since January 2007 and has been its President since June 2008. As President and Chief Executive Officer, Mr. Melo has led Amyris throug ...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD9.64M) is above average for companies of similar size in the US market ($USD1.72M).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
John Melo
President13.1yrsUS$9.64m0.093% $444.2k
Eduardo Alvarez
Chief Operating Officer2.3yrsUS$1.98m0.16% $776.2k
Nicole Kelsey
General Counsel & Secretary2.5yrsUS$1.20m0.023% $109.5k
Kathleen Valiasek
Chief Business Officer0.7yrsUS$2.02m0.062% $296.5k
Fernando de Castro Reinach
Consultant1.6yrsUS$27.75kno data
Jonathan Wolter
Interim Chief Financial Officer0.7yrsno datano data
Anthony Hughes
Chief Accounting Officer1.7yrsno data0.034% $162.7k
Peter DeNardo
Senior Director of Investor Relations & Corporate Communications0yrsno datano data
Beth Baker Bannerman
Senior Vice President of Corporate Communications & Engagement0yrsno datano data
Christine Ofori
Chief People Officer0yrsno datano data

1.7yrs

Average Tenure

55yo

Average Age

Experienced Management: AMRS's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
John Melo
President13.1yrsUS$9.64m0.093% $444.2k
Frank F. Kung
Independent Director2.3yrsUS$73.35kno data
L. Doerr
Independent Director13.8yrsUS$82.35k36.75% $175.1m
Steven Mills
Independent Director1.5yrsUS$52.98k0.010% $48.8k
Geoffrey Duyk
Interim Independent Chair of the Board5.8yrsUS$13.17k0.0029% $14.1k
Carole Piwnica
Independent Director10.4yrsUS$87.85k0.0054% $25.6k
Patrick Yang
Independent Director5.6yrsUS$78.35k0.028% $135.7k
R. Williams
Independent Director6.8yrsUS$103.35k0.0051% $24.3k
Christoph Goppelsroeder
Director2.3yrsUS$40.00kno data
Philip Eykerman
Director2.8yrsUS$73.35k0.0030% $14.2k

5.7yrs

Average Tenure

62yo

Average Age

Experienced Board: AMRS's board of directors are considered experienced (5.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: AMRS insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 62.5%.


Top Shareholders

Company Information

Amyris, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Amyris, Inc.
  • Ticker: AMRS
  • Exchange: NasdaqGS
  • Founded: 2003
  • Industry: Specialty Chemicals
  • Sector: Materials
  • Market Cap: US$476.454m
  • Shares outstanding: 144.82m
  • Website: https://www.amyris.com

Number of Employees


Location

  • Amyris, Inc.
  • 5885 Hollis Street
  • Suite 100
  • Emeryville
  • California
  • 94608
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AMRSNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDSep 2010
3A01DB (Deutsche Boerse AG)YesCommon StockDEEURSep 2010

Biography

Amyris, Inc. operates as an integrated renewable products company. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients, and consumer products. The company delivers its No Compromise products and services in markets, such as specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/25 01:37
End of Day Share Price2020/02/24 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.